China In-vitro Diagnostic Reagent Industry Report 2017-2021 - Research and Markets

DUBLIN, Apr. 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Research Report on China In-vitro Diagnostic Reagent Industry, 2017-2021" report to their offering.

The market size of China in-vitro diagnostic reagents reached about CNY 26 billion (USD 3.9 billion) in 2016, of which the leading three were immune, biochemical and molecular products.

The global in-vitro diagnostic market is mature and the concentration rate is high. Top 5 manufacturers of global in-vitro diagnostic industry are Roche, Siemens, JNJ, Abbott and Beckman with an aggregate market share of over 60% in the globe as monopolies.

The market size of in-vitro diagnostics is closely related to the population base, medical treatment expenses per capita, medical care level and medical technology together with service levels of a country. At present, the demand market of global in-vitro diagnostics is mainly distributed in developed economies such as North America, Europe and Japan.

In China, major consumption demand for in-vitro diagnostic reagents derives from medical testing and blood screening. Medical testing is the major consumer of in-vitro diagnostic reagents including hospital clinical laboratory, physical examination center, independent laboratory and epidemic prevention station. Meanwhile, blood screening is mainly applied in blood collection and supply departments including various blood stations and blood product manufacturers. Presently, hospitals are major demand markets of in-vitro diagnostic reagents in China.

China's population accounts for more than 20% of the world, while the market share of in-vitro diagnostics is less than 10%. In 2016, the annual consumption per capita of China's in-vitro diagnostic products was less than USD 3, while that of developed countries reached USD 25 to USD 30. Therefore, there is a wide increase space for China's in-vitro diagnostic market. It is estimated that from 2017 to 2021, the market scale of China's in-vitro diagnostic market will develop at a growth rate exceeding that of the average global level to about CNY 49 billion with the CAGR of over 10%. Meanwhile, major shares will be occupied by immune and biochemical products, and molecular products will grow with a higher proportion.